Leukemia News and Research RSS Feed - Leukemia News and Research

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
BCR-ABL halving time indicates CML prognosis during front-line TKI

BCR-ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers. [More]
Bosutinib shows 'low' vascular, cardiac event risk profile

Bosutinib shows 'low' vascular, cardiac event risk profile

Third-generation tyrosine kinase inhibitor study findings suggest that bosutinib is associated with a low risk of vascular and cardiac events in patients undergoing first-line or subsequent treatment for chronic myeloid leukaemia. [More]
Imatinib-related symptom burden linked to adherence in Indian CML patients

Imatinib-related symptom burden linked to adherence in Indian CML patients

Research shows low adherence to imatinib in Indian patients with chronic myeloid leukaemia, with an association between nonadherence and worse symptom burden related to treatment. [More]
Frontline nilotinib supported for newly diagnosed CP-CML

Frontline nilotinib supported for newly diagnosed CP-CML

Long-term results from the ENESTnd trial indicate a favourable risk-benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase-chronic myeloid leukaemia diagnosis. [More]
Pre-TKI cytokine profiling predicts CP-CML outcome

Pre-TKI cytokine profiling predicts CP-CML outcome

Measuring levels of transforming growth factor-α and interleukin-6 may help identify patients with newly diagnosed chronic phase-chronic myeloid leukaemia at risk of a poor outcome from tyrosine kinase inhibitor therapy, research suggests. [More]
Newly discovered player in epigenetic regulation closely linked to known cancer promoters

Newly discovered player in epigenetic regulation closely linked to known cancer promoters

If genes form the body's blueprint, then the layer of epigenetics decides which parts of the plan get built. Unfortunately, many cancers hijack epigenetics to modulate the expression of genes, thus promoting cancer growth and survival. [More]
NanoString launches new nCounter Vantage assays that power 3D Biology experiments in cancer research

NanoString launches new nCounter Vantage assays that power 3D Biology experiments in cancer research

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the introduction of nCounter Vantage, a portfolio of assays that power 3D Biology™ experiments in cancer research, including immuno-oncology. [More]
Intestinal bacteria can be used to reduce cancer risk, reveals UCLA study

Intestinal bacteria can be used to reduce cancer risk, reveals UCLA study

Researchers have shown that various types of intestinal bacteria might be factors in both causing and preventing obesity, and in other conditions and diseases. Now, a UCLA study suggests that it could also potentially be used to reduce the risk for some types of cancer. [More]
Researchers reach milestone in developing non-hormonal approach to male contraception

Researchers reach milestone in developing non-hormonal approach to male contraception

Researchers studying strategies to develop a non-hormonal approach to male contraception have reached an important milestone in their work, discovering a way to produce a key enzyme found only in sperm in sufficient quantities that they can begin designing drugs to stop the sperm from swimming to the egg. [More]
Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this disease and research new therapeutic targets. [More]
CCCBD offers promising new investigational therapy to treat childhood ALL

CCCBD offers promising new investigational therapy to treat childhood ALL

The Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles is one of the first sites in the world to offer a promising new investigational therapy to treat pediatric acute lymphoblastic leukemia (ALL). [More]
High out-of-pocket costs linked to lower use of specialty drugs

High out-of-pocket costs linked to lower use of specialty drugs

"Specialty drugs" have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival. [More]
Promising UCLA discovery could lead to new method for improving cancer treatments

Promising UCLA discovery could lead to new method for improving cancer treatments

A promising new discovery by UCLA scientists could lead to a new method of identifying cancer patients that express high levels of an enzyme and are more likely to respond to cancer treatments. [More]
Gleevec could be novel therapeutic agent for type 2 diabetes

Gleevec could be novel therapeutic agent for type 2 diabetes

The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto another possible use for it, curing type 2 diabetes. [More]
Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

The second annual Kevin Rudi Superhero 5K Fun Run will start and end by the Memorial Stadium Field House in Las Cruces. Money raised for sarcoma research will benefit The University of New Mexico Comprehensive Cancer Center. [More]
Mutations in cancerous lymphoma cells break through four protein locks

Mutations in cancerous lymphoma cells break through four protein locks

Protein chemists at Johns Hopkins report they are closer to explaining why certain blood cancers are able to crack a molecular security system and run rampant. [More]
Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Metabolite in gut microbiome could improve outcomes after bone marrow transplant

Could playing better defense make bone marrow transplants more successful? With this question in mind, researchers began looking at whether the trillions of little bugs and bacteria living in our gastrointestinal tract could be the key to playing defense. [More]
Four key genes govern growth, multiplication of blood stem cells

Four key genes govern growth, multiplication of blood stem cells

An important element in getting blood stem cells to multiply outside the body is to understand which of the approximately 20,000 genes in the human body control their growth. Now a research team at Lund University in Sweden has studied close to 15,000 of these genes alongside each other. [More]
Novel compound shows promise as potential treatment for acute myeloid leukemia

Novel compound shows promise as potential treatment for acute myeloid leukemia

A novel compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease. [More]

MRX-2843 treatment improves survival of acute myeloid leukemia patients

Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, and several clinical trials are testing FLT3 inhibitors. [More]
Advertisement